Denali Therapeutics Prices Public Offering at $200 Million
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Offering Size: Denali Therapeutics announced a public offering of 9,142,857 shares at $17.50 per share, expecting to raise approximately $200 million, which will significantly bolster its funding for research and operations.
- Pre-Funded Warrants: The offering includes pre-funded warrants allowing certain investors to purchase 2,285,714 shares at $17.49 each, enhancing investor engagement and participation in the capital raise.
- Underwriter Selection: The offering is managed by Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies, reflecting strong market confidence in Denali and providing robust promotional capabilities for the company.
- Future Outlook: Denali expects to close the offering on December 11, 2025, subject to customary closing conditions, with proceeds aimed at advancing its biotherapeutics designed to cross the blood-brain barrier, thereby strengthening its market position in neurodegenerative diseases.
DNLI.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on DNLI
Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 31.14 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.690
Low
26.00
Averages
31.14
High
37.00
Current: 19.690
Low
26.00
Averages
31.14
High
37.00
Wedbush
Laura Chico
Outperform
maintain
$30 -> $31
2025-12-05
New
Reason
Wedbush
Laura Chico
Price Target
$30 -> $31
2025-12-05
New
maintain
Outperform
Reason
Wedbush analyst Laura Chico raised the firm's price target on Denali Therapeutics to $31 from $30 and keeps an Outperform rating on the shares. The firm says most notable in the Denali Investor Day event, management indicated the tivi review remains ongoing with its late-cycle meeting wrapped, and key commercial hires are already made. No changes were made to Wedbush's tivi revenue estimates, which continues to assume modest revenue in 2026 and increasing to $433M by FY30.
BofA
BofA
Buy
maintain
$26 -> $29
2025-12-05
New
Reason
BofA
BofA
Price Target
$26 -> $29
2025-12-05
New
maintain
Buy
Reason
BofA raised the firm's price target on Denali Therapeutics to $29 from $26 and keeps a Buy rating on the shares after the company hosted an investor day to outline its three-year growth strategy. Following the event, the firm introduced the royalty agreement with Royalty Pharma into its model and adjusted its cost of goods sold estimates based on management commentary, while also increasing its gross pipeline value to $4.5B from $4B.
BofA
Buy
maintain
$27 -> $26
2025-11-17
Reason
BofA
Price Target
$27 -> $26
2025-11-17
maintain
Buy
Reason
BofA lowered the firm's price target on Denali Therapeutics to $26 from $27 and keeps a Buy rating on the shares. The firm made changes to its model following the company's Q3 update, noting that Denali management highlighted that they continue to engage with the FDA on the ongoing biologics license application review of tividefusp alfa for Hunter syndrome following the recent extension with new target action date of April 5, 2026.
BofA
Tazeen Ahmad
Buy
downgrade
$27 -> $26
2025-11-16
Reason
BofA
Tazeen Ahmad
Price Target
$27 -> $26
2025-11-16
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $26 from $27 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.
See All Ratings
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contributed to Clene Inc.'s after-hours stock price increase?
Why did Werewolf Therapeutics' stock rise despite no new announcements?
How might Clene's investor call impact its stock performance in the future?
Will Biomea Fusion's upcoming presentation lead to sustained stock growth?